Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis

Michihito Sato, Kumiko Ohtsuka, Ryo Takahashi, Kuninobu Wakabayashi, Tsuyoshi Odai, Takeo Isozaki, Nobuyuki Yajima, Yusuke Miwa, Tsuyoshi KasamaDivision of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanObjective: To examine the relationship between serum chem...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michihito Sato, Kumiko Ohtsuka, Ryo Takahashi, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/7c2f8c664c644d5296fad4e2e0c284d6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7c2f8c664c644d5296fad4e2e0c284d6
record_format	dspace
spelling	oai:doaj.org-article:7c2f8c664c644d5296fad4e2e0c284d62021-12-02T02:57:45ZInvolvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis1179-156Xhttps://doaj.org/article/7c2f8c664c644d5296fad4e2e0c284d62011-01-01T00:00:00Zhttp://www.dovepress.com/involvement-of-cx3cl1cx3cr1-axis-in-etanercept-therapy-for-patients-wi-a6025https://doaj.org/toc/1179-156XMichihito Sato, Kumiko Ohtsuka, Ryo Takahashi, Kuninobu Wakabayashi, Tsuyoshi Odai, Takeo Isozaki, Nobuyuki Yajima, Yusuke Miwa, Tsuyoshi KasamaDivision of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanObjective: To examine the relationship between serum chemokine levels and patient responsiveness in rheumatoid arthritis (RA) patients to etanercept (ETN) and the influence of ETN administration on serum chemokine levels.Methods: Serum levels of the chemokines CX3CL1, CXCL8, CXCL10, and CCL3 were quantified prior to (at baseline) and after 14 weeks of treatment with ETN in 20 patients using enzyme-linked immunosorbent assay. Disease status was assessed using the Disease Activity Score (DAS28). The response to ETN was classified according to the European League Against Rheumatism (EULAR) response criteria.Results: By 14 weeks, ETN produced a significant overall reduction in DAS28 among the 20 patients with RA; eight patients achieved a good response, and 10 patients achieved a moderate response based on EULAR response criteria. A significant reduction in CX3CL1 was observed in the responsive group, although ETN treatment had no significant effect on the serum levels of the other three chemokines. In addition, the messenger ribonucleic acid expression of CX3CR1 in peripheral blood mononuclear cells and the cell-surface expression of CX3CR1 protein in peripheral blood CD8+CD3+ T cells were both decreased after ETN treatment.Conclusions: Our results suggest that the CX3CL1 and CX3CR1 in patients with active RA may be sensitive to antitumor necrosis factor-&alpha; therapy and confirm that CX3CL1/CX3CR1 axis plays a crucial role in the pathogenesis of RA.Keywords: rheumatoid arthritis, chemokine, CX3CL1, CX3CR1, TNF antagonist, etanercept Michihito SatoKumiko OhtsukaRyo Takahashiet alDove Medical PressarticleDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol 2011, Iss default, Pp 1-7 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the musculoskeletal system RC925-935
spellingShingle	Diseases of the musculoskeletal system RC925-935 Michihito Sato Kumiko Ohtsuka Ryo Takahashi et al Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
description	Michihito Sato, Kumiko Ohtsuka, Ryo Takahashi, Kuninobu Wakabayashi, Tsuyoshi Odai, Takeo Isozaki, Nobuyuki Yajima, Yusuke Miwa, Tsuyoshi KasamaDivision of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanObjective: To examine the relationship between serum chemokine levels and patient responsiveness in rheumatoid arthritis (RA) patients to etanercept (ETN) and the influence of ETN administration on serum chemokine levels.Methods: Serum levels of the chemokines CX3CL1, CXCL8, CXCL10, and CCL3 were quantified prior to (at baseline) and after 14 weeks of treatment with ETN in 20 patients using enzyme-linked immunosorbent assay. Disease status was assessed using the Disease Activity Score (DAS28). The response to ETN was classified according to the European League Against Rheumatism (EULAR) response criteria.Results: By 14 weeks, ETN produced a significant overall reduction in DAS28 among the 20 patients with RA; eight patients achieved a good response, and 10 patients achieved a moderate response based on EULAR response criteria. A significant reduction in CX3CL1 was observed in the responsive group, although ETN treatment had no significant effect on the serum levels of the other three chemokines. In addition, the messenger ribonucleic acid expression of CX3CR1 in peripheral blood mononuclear cells and the cell-surface expression of CX3CR1 protein in peripheral blood CD8+CD3+ T cells were both decreased after ETN treatment.Conclusions: Our results suggest that the CX3CL1 and CX3CR1 in patients with active RA may be sensitive to antitumor necrosis factor-&alpha; therapy and confirm that CX3CL1/CX3CR1 axis plays a crucial role in the pathogenesis of RA.Keywords: rheumatoid arthritis, chemokine, CX3CL1, CX3CR1, TNF antagonist, etanercept
format	article
author	Michihito Sato Kumiko Ohtsuka Ryo Takahashi et al
author_facet	Michihito Sato Kumiko Ohtsuka Ryo Takahashi et al
author_sort	Michihito Sato
title	Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
title_short	Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
title_full	Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
title_fullStr	Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
title_full_unstemmed	Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
title_sort	involvement of cx3cl1/cx3cr1 axis in etanercept therapy for patients with active rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/7c2f8c664c644d5296fad4e2e0c284d6
work_keys_str_mv	AT michihitosato involvementofcx3cl1cx3cr1axisinetanercepttherapyforpatientswithactiverheumatoidarthritis AT kumikoohtsuka involvementofcx3cl1cx3cr1axisinetanercepttherapyforpatientswithactiverheumatoidarthritis AT ryotakahashi involvementofcx3cl1cx3cr1axisinetanercepttherapyforpatientswithactiverheumatoidarthritis AT etal involvementofcx3cl1cx3cr1axisinetanercepttherapyforpatientswithactiverheumatoidarthritis
_version_	1718402050299002880

Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis

Ejemplares similares